[go: up one dir, main page]

AR089727A1 - Compuesto de pirazin-carboxamida - Google Patents

Compuesto de pirazin-carboxamida

Info

Publication number
AR089727A1
AR089727A1 ARP130100118A ARP130100118A AR089727A1 AR 089727 A1 AR089727 A1 AR 089727A1 AR P130100118 A ARP130100118 A AR P130100118A AR P130100118 A ARP130100118 A AR P130100118A AR 089727 A1 AR089727 A1 AR 089727A1
Authority
AR
Argentina
Prior art keywords
substituted
lower alkyl
alkylene
egfr
mutation
Prior art date
Application number
ARP130100118A
Other languages
English (en)
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48799179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089727(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AR089727A1 publication Critical patent/AR089727A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

El compuesto de pirazin-carboxamida de la presente tiene una acción inhibidora sobre una quinasa con mutación T790M en el EGFR, y se puede usar como agente para prevenir y/o tratar el cáncer positivo con mutación T790M en el EGFR; en otra forma de realización, cáncer de pulmón positivo con mutación T790M en el EGRF; aún en otra forma de realización, cáncer de pulmón de células no pequeñas positivo con mutación T790M en el EGFR; también en otra forma de realización, cáncer de proteínas positivo con mutación T790M en el EGRF; en una forma de realización diferente, cáncer de pulmón de proteínas positivo con mutación T790M en el EGRF; aún en una forma de realización diferente, cáncer resistente al inhibidor de la tirosina quinasa en el EGFR; aún en una forma de realización diferente, cáncer de pulmón resistente al inhibidor de la tirosina quinasa en el EGFR; y también en otra forma de realización diferente, cáncer de pulmón de células no pequeñas resistente al inhibidor de la tirosina quinasa en el EGFR y similares. Reivindicación 1: Un compuesto de la fórmula (1) o una de sus sales, donde R¹ representa alquilo inferior que puede estar sustituido, -O-alquilo inferior que puede estar sustituido, -NH₂, -NH-alquilo inferior que puede estar sustituido, -N(alquilo inferior que puede estar sustituido)₂, -L⁴-cicloalquilo que puede estar sustituido, -L⁴-arilo que puede estar sustituido, -L⁴-grupo heterocíclico aromático que puede estar sustituido, o -L⁴-grupo heterocíclico no aromático que puede estar sustituido; el anillo A representa areno que puede estar sustituido o un heterociclo aromático que puede estar sustituido; L¹ representa -O- o -NH-; R² representa H, halógeno, -OH, -NR⁵R⁶, -CONH₂, -CN, -L⁴-cicloalquilo que puede estar sustituido, -L⁴-arilo que puede estar sustituido, -L⁴-grupo heterocíclico aromático que puede estar sustituido, -L⁴-grupo heterocíclico no aromático que puede estar sustituido, alquilo inferior que puede estar sustituido, alquenilo inferior que puede estar sustituido, o alquinilo inferior que puede estar sustituido; L² representa -O-, -S(O)ₚ-, -NH-, -N(CH₃)-, -NHCH₂-, -NHCH₂CH₂-, -OCH₂- o una unión; Y representa anillo X o una unión; el anillo X representa cicloalcano que puede estar sustituido, areno que puede estar sustituido, un heterociclo aromático que puede estar sustituido, o un heterociclo no aromático que puede estar sustituido; L³ representa -O-, -NH-, -N(alquilo inferior que puede estar sustituido)-, -N(cicloalquilo que puede estar sustituido), -alquileno inferior que puede estar sustituido-, -alquileno inferior que puede estar sustituido-NH-, -NH-alquileno inferior que puede estar sustituido-, -alquileno inferior que puede estar sustituido-N(alquilo inferior que puede estar sustituido)-, -N(alquilo inferior que puede estar sustituido)-alquileno inferior que puede estar sustituido- o una unión; M representa -C(O)- o -S(O)₂-; R³ representa H o alquilo inferior que puede estar sustituido; R⁴ representa alquilo inferior que puede estar sustituido con uno o más sustituyentes que se seleccionan del grupo que consiste de -OH, halógeno, -NH₂, -NH-(alquilo inferior que puede estar sustituido), -N(alquilo inferior que puede estar sustituido)₂, y un grupo heterocíclico no aromático que puede estar sustituido, o H; R⁵ y R⁶ son iguales o diferentes entre sí, y representan H o alquilo inferior que puede estar sustituido; L⁴s son iguales o diferentes entre sí, y representan alquileno inferior que puede estar sustituido-, -NH-, -O-, -O-alquileno inferior que puede estar sustituido-, -alquileno inferior que puede estar sustituido-O- o una unión; y p representa 0, 1 ó 2.
ARP130100118A 2012-01-17 2013-01-15 Compuesto de pirazin-carboxamida AR089727A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012007525 2012-01-17

Publications (1)

Publication Number Publication Date
AR089727A1 true AR089727A1 (es) 2014-09-10

Family

ID=48799179

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100118A AR089727A1 (es) 2012-01-17 2013-01-15 Compuesto de pirazin-carboxamida

Country Status (29)

Country Link
US (1) US9085540B2 (es)
EP (1) EP2805940B1 (es)
JP (1) JP5532366B2 (es)
KR (1) KR101985050B1 (es)
CN (1) CN104080774B (es)
AR (1) AR089727A1 (es)
AU (1) AU2013210438B2 (es)
BR (1) BR112014017466A8 (es)
CA (1) CA2860765C (es)
CY (1) CY1118644T1 (es)
DK (1) DK2805940T3 (es)
EA (1) EA026353B1 (es)
ES (1) ES2613399T3 (es)
HR (1) HRP20170226T1 (es)
HU (1) HUE033177T2 (es)
IL (1) IL233437A (es)
LT (1) LT2805940T (es)
ME (1) ME02648B (es)
MX (1) MX355434B (es)
PH (1) PH12014501456A1 (es)
PL (1) PL2805940T3 (es)
PT (1) PT2805940T (es)
RS (1) RS55704B1 (es)
SI (1) SI2805940T1 (es)
SM (2) SMT201700094T1 (es)
TW (1) TWI532727B (es)
UA (1) UA111010C2 (es)
WO (1) WO2013108754A1 (es)
ZA (1) ZA201405045B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014163161A1 (ja) * 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物
HUE044683T2 (hu) * 2013-10-21 2019-11-28 Merck Patent Gmbh Heteroaril vegyületek mint BTK inhibitorok és alkalmazásuk
RU2646758C2 (ru) * 2013-12-05 2018-03-07 Ф. Хоффманн-Ля Рош Аг Гетероарил пиридоны и азапиридоны с электрофильной функциональностью
AU2014360446A1 (en) 2013-12-05 2016-06-09 Pharmacyclics, Llc Inhibitors of Bruton's tyrosine kinase
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
AU2015266552A1 (en) * 2014-05-28 2016-12-01 Astellas Pharma Inc. Pharmaceutical composition comprising pyrazine carboxamide compound as active ingredient
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
WO2016121777A1 (ja) * 2015-01-28 2016-08-04 アステラス製薬株式会社 ピラジンカルボキサミド化合物の製造方法及びその合成中間体
EP3290036A4 (en) * 2015-04-27 2019-01-02 Astellas Pharma Inc. Stabilized pharmaceutical composition
JP2018104290A (ja) * 2015-04-28 2018-07-05 アステラス製薬株式会社 ピラジンカルボキサミド化合物を有効成分とする医薬組成物
EP3310776A4 (en) * 2015-06-02 2019-01-16 Pharmacyclics LLC BRUTON TYROSINE KINASE HEMMER
JP6878316B2 (ja) * 2015-06-19 2021-05-26 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
JP2019014653A (ja) * 2015-11-27 2019-01-31 アステラス製薬株式会社 がん免疫を介したがん治療方法
KR20180094923A (ko) * 2015-12-24 2018-08-24 교와 핫꼬 기린 가부시키가이샤 α, β 불포화 아미드 화합물
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
WO2018013597A1 (en) * 2016-07-12 2018-01-18 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
JPWO2018079570A1 (ja) * 2016-10-26 2019-09-19 アステラス製薬株式会社 安定な医薬組成物
WO2018103663A1 (zh) * 2016-12-09 2018-06-14 深圳市塔吉瑞生物医药有限公司 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途
TWI804498B (zh) * 2017-06-23 2023-06-11 日商協和麒麟股份有限公司 α、β不飽和醯胺化合物
TWI798334B (zh) * 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｒｂｂ／ｂｔｋ抑制劑
CN112839930B (zh) 2018-09-30 2022-03-15 南京明德新药研发有限公司 作为flt3和axl抑制剂的3,9-二氮杂螺[5,5]十一烷类化合物
CN112062728A (zh) * 2019-05-25 2020-12-11 上海鑫凯化学科技有限公司 一种3,5-二氯-6-乙基吡嗪甲酰胺的合成方法
CN114728905B (zh) * 2019-11-13 2025-08-01 基因泰克公司 治疗性化合物及使用方法
CN111266090B (zh) * 2020-02-19 2022-11-15 渤海大学 一种快速吸附和选择性分离阳离子染料污染物的吸附分离材料及其应用
US20230167099A1 (en) * 2020-06-01 2023-06-01 Wigen Biomedicine Technology (shanghai) Co., Ltd. New pyrazine compound
CN113943288A (zh) * 2020-07-17 2022-01-18 微境生物医药科技(上海)有限公司 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
MX2023003731A (es) * 2020-09-30 2023-04-24 Beigene Ltd Compuestos de 3-[(1h-pirazol-4-il)oxi]pirazin-2-amina como inhibidores de hpk1, y uso de los mismos.
JP2024509625A (ja) 2021-03-15 2024-03-04 ノバルティス アーゲー ベンゾイソオキサゾール誘導体及びその使用
IL313670A (en) 2021-12-30 2024-08-01 Biomea Fusion Inc Pyrazine compounds as inhibitors of FLT3

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
AU2003304497B2 (en) 2003-09-15 2010-06-24 Wyeth Llc Substituted quinolines as protein tyrosine kinase enzyme inhibitors
SI1746999T1 (sl) 2004-05-06 2012-01-31 Warner Lambert Co 4-fenilamino-kinazolin-6-il-amidi
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
CA2702674C (en) 2007-10-19 2016-05-03 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CN102066339B (zh) * 2008-04-16 2014-09-24 波托拉医药品公司 作为syk或jak蛋白激酶抑制剂的2，6-二氨基-嘧啶-5-基甲酰胺类化合物
CA2960692C (en) * 2008-04-16 2019-09-24 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI458721B (zh) 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
DK2428508T3 (en) 2009-05-08 2016-02-01 Astellas Pharma Inc Diamino heterocyclic carboxamide COMPOUND
WO2011140338A1 (en) 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith

Also Published As

Publication number Publication date
PH12014501456A1 (en) 2014-10-08
BR112014017466A2 (pt) 2017-06-13
EP2805940A1 (en) 2014-11-26
WO2013108754A1 (ja) 2013-07-25
LT2805940T (lt) 2017-01-10
EA026353B1 (ru) 2017-03-31
AU2013210438B2 (en) 2016-11-10
JP5532366B2 (ja) 2014-06-25
HUE033177T2 (en) 2017-11-28
SMT201700094T1 (it) 2017-03-08
HRP20170226T1 (hr) 2017-04-07
PL2805940T3 (pl) 2017-06-30
BR112014017466A8 (pt) 2017-07-04
CN104080774A (zh) 2014-10-01
SI2805940T1 (sl) 2017-04-26
CA2860765A1 (en) 2013-07-25
US20140323463A1 (en) 2014-10-30
SMT201700094B (it) 2017-03-08
RS55704B1 (sr) 2017-07-31
JPWO2013108754A1 (ja) 2015-05-11
CA2860765C (en) 2018-06-26
EP2805940A4 (en) 2015-04-15
HK1203491A1 (en) 2015-10-30
CY1118644T1 (el) 2017-07-12
TWI532727B (zh) 2016-05-11
IL233437A0 (en) 2014-08-31
EP2805940B1 (en) 2016-11-23
DK2805940T3 (en) 2017-02-06
MX355434B (es) 2018-04-18
EA201491371A1 (ru) 2014-11-28
ME02648B (me) 2017-06-20
MX2014008647A (es) 2014-11-25
US9085540B2 (en) 2015-07-21
UA111010C2 (uk) 2016-03-10
PT2805940T (pt) 2017-02-03
IL233437A (en) 2017-01-31
KR101985050B1 (ko) 2019-05-31
TW201341373A (zh) 2013-10-16
KR20140114404A (ko) 2014-09-26
CN104080774B (zh) 2017-02-22
ZA201405045B (en) 2016-01-27
AU2013210438A1 (en) 2014-07-17
ES2613399T3 (es) 2017-05-24

Similar Documents

Publication Publication Date Title
AR089727A1 (es) Compuesto de pirazin-carboxamida
AR097866A1 (es) Derivados de 4-azaindol
AR099785A1 (es) Compuestos heteroarilos y su uso como medicamentos
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
MX2018009494A (es) Compuestos de piperidina sustituidos y su uso.
AR100137A1 (es) Compuestos 4-amino-imidazoquinolina
AR098337A1 (es) Triazolopirazina
IL263163B (en) Substituted pyridines as inhibitors of dnmt1
IL287679A (en) Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CO2017003279A2 (es) Compuestos y composiciones farmacéuticamente aceptables de los mismos, eficaces como inhibidores de mk2
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
AR096621A1 (es) Inhibidores de isómeros de la fosfatidilinositol 3-quinasa (pi3k)
MX2017002206A (es) Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos.
EA201790317A1 (ru) Ингибиторы smyd
BR112017012707A2 (pt) compostos inibidores de parg
BR112018013977A2 (pt) derivados de quinolin-2-ona
UY36314A (es) NUEVOS COMPUESTOS ANTAGONISTAS DE INTEGRINA avß6.
IL251818B (en) Crystalline forms of 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine
AR089623A1 (es) Inhibidores de iap
MX2016013600A (es) Método para tratar adenocarcinoma de pulmón.
UY36709A (es) Moduladores de ror gamma (ror¿)
AR099646A1 (es) Fotoestabilizantes de aminas impedidas
CO2017005498A2 (es) Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina

Legal Events

Date Code Title Description
FB Suspension of granting procedure